Avenge Bio, a cell therapy biotech from Rice, is closed

Cell therapy startup Avenge Bio has shut down, Endpoints News has learned.

The company ceased all operations and sold its lead asset, Xontogeny CEO Chris …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients – Pharmaceutical Technology

Datopotamab deruxtecan is comprised of a TROP2-targeting antibody conjugated to a TOP1-inhibitor payload. Image: Getty Images/ wildpixel New data from the TROPION-Lung01 trial show datopotamab

September 10, 2024

Medacta publishes 2024 Annual General Meeting invitation – Biotech Investments

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2024 Annual General Meeting invitation 09.04.2024 / 07:00 CET/CEST Media Release Medacta publishes

April 10, 2024

Postpartum individuals more likely to have medical debt, study finds

For some families, the year after childbirth may not only mean loads of diapers but stacks of unpaid medical bills as well.

September 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.